Effect of S53P4 bioactive glass and low-level laser therapy on calvarial bone repair in rats submitted to zoledronic acid therapy.

Autor:	Bellato CP; Fellow PhD degree. Postgraduate Program in Oral and Maxillofacial Surgery. Assistant Professor. Department Oral and Maxillofacial Surgery - Dental School - Universidade do Oeste Paulista - Presidente Prudente (SP), Brazil., Oliveira DL; PhD, Assistant Professor. Oral and Maxillofacial Surgery - Department Oral and Maxillofacial Surgery - Dental School - Universidade do Oeste Paulista - Presidente Prudene (SP), Brazil., Kasaya MVS; PhD. Oral and Maxillofacial Surgery - Department of Postgraduate - Dental School - Centro Universitário Sagrado Coração - Bauru (SP), Brazil., Moreira D; PhD. Oral and Maxillofacial Surgery - Department of Postgraduate - Dental School - Centro Universitário Sagrado Coração - Bauru (SP), Brazil., Cini MA; PhD. Oral and Maxillofacial Surgery - Department of Postgraduate - Dental School - Centro Universitário Sagrado Coração - Bauru (SP), Brazil., Saraiva PP; PhD, Assistant Professor. Basic Science - Oral Biology - Universidade do Oeste Paulista - Jau (SP), Brazil., Gulinelli JL; PhD, Assistant Professor. Oral and Maxillofacial Surgery - Oral Sin - Londrina (PR), Brazil., Santos PL; PhD, Assistant Professor. Oral and Maxillofacial Surgery - Department of Health Sciences - Dental School - Universidade de Araraquara - Araraquara (SP), Brazil.
Jazyk:	angličtina
Zdroj:	Acta cirurgica brasileira [Acta Cir Bras] 2021 Jul 09; Vol. 36 (6), pp. e360603. Date of Electronic Publication: 2021 Jul 09 (Print Publication: 2021).
DOI:	10.1590/ACB360603
Abstrakt:	Purpose: To evaluate the influence of bioactive glass and photobiomodulation therapy (PBMT) in calvarial bone repair process in rats submitted to zoledronic acid therapy. Methods: Twenty-four rats were selected and treated with the dose of 0.035 mg/kg of zoledronic acid every two weeks, totalizing eight weeks, to induce osteonecrosis. After the drug therapy, surgical procedure was performed to create 5-mm diameter parietal bone defects in the calvarial region. The rats were then randomly assigned to groups according to the following treatments: AZC: control group, treated with blood clot; AZBIO: bone defect filled with bioactive glass; AZL: treated with blood clot and submitted to PBMT; and AZBIOL: treated with bioactive glass S53P4 and submitted to PBMT. Tissue samples were collected and submitted to histomorphometric analysis after 14 and 28 days. Results: At 14 days, bone neoformation in the AZBIO (52.15 ± 9.77) and AZBIOL (49.77 ± 13.58) groups presented higher values (p ≤ 0.001) compared to the AZC (23.35 ± 10.15) and AZL groups (23.32 ± 8.75). At 28 days, AZBIO (80.24 ± 5.41)still presented significant higher bone recovery values when compared to AZC (59.59 ± 16.92)and AZL (45.25 ± 5.41) groups (p = 0.048). In the 28-day period, the AZBIOL group didn't show statistically significant difference with the other groups (71.79 ± 29.38). Conclusions: The bioactive glass is an effective protocol to stimulate bone neoformation in critical defects surgically created in rats with drug induced osteonecrosis, in the studied periods of 14 and 28 days.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu